Compare IBRX & HQY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | HQY |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.1B |
| IPO Year | 2015 | 2014 |
| Metric | IBRX | HQY |
|---|---|---|
| Price | $9.17 | $93.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $12.57 | ★ $115.00 |
| AVG Volume (30 Days) | ★ 11.7M | 891.5K |
| Earning Date | 05-08-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.71 | ★ 125.69 |
| EPS | N/A | ★ 0.82 |
| Revenue | $113,288,000.00 | ★ $229,525,000.00 |
| Revenue This Year | $88.59 | $8.57 |
| Revenue Next Year | $131.15 | $8.42 |
| P/E Ratio | ★ N/A | $112.57 |
| Revenue Growth | ★ 668.31 | 28.68 |
| 52 Week Low | $1.95 | $72.76 |
| 52 Week High | $12.43 | $105.96 |
| Indicator | IBRX | HQY |
|---|---|---|
| Relative Strength Index (RSI) | 70.92 | 65.34 |
| Support Level | $6.69 | $89.80 |
| Resistance Level | $9.54 | $97.65 |
| Average True Range (ATR) | 0.55 | 2.87 |
| MACD | 0.23 | 0.47 |
| Stochastic Oscillator | 90.94 | 86.97 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.